GL1X · GenesisL1 explorer

MolNFT v1 · #181888 · protein

Bovine sigma-2 receptor bound to Z1241145220

7M95 · Sigma intracellular receptor 2: “Bovine sigma-2 receptor bound to Z1241145220”. X-ray diffraction, 2 ligands (ZNC, CLR), 5 pockets (best druggability 0.71). MolNFT v1 #181888 on GenesisL1: 3D structure, binding sites and pockets in…

PDB
7M95
Type
protein
Length
331 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Sigma intracellular receptor 2
UniProt
Q3MHW7
Ligands
ZNC, CLR
Pockets
5 · best druggability 0.71

Structure

x-ray diffraction · 2 distinct chains · 74% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASigma intracellular receptor 2protein16474% helix, 0% strandQ3MHW7
BSigma intracellular receptor 2protein16774% helix, 0% strandQ3MHW7

Ligands and binding sites

  • ZNC · 3-[1-(3-phenylpropyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine · ligand · 2 copies · chains A, B
  • CLR · Cholesterol · ligand · chains A
  • OLC · (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate · additive · 9 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11410.710.9020ZNC
21580.690.8822ZNC
32760.520.7435empty
41610.490.7618OLC
51320.470.7715OLC

Interfaces

1 interface between chains.

  • A–B · 883 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 7M95 · Bovine sigma-2 receptor bound to Z1241145220 · the same entry in another collection · chain A against A, TM-score 1.00
  • Q3MHW7 · AlphaFold monomer V2.0 prediction for sigma intracellular receptor 2 (Q3MHW7) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.